CLS and advanced fiber tools enter strategic partnership to pursue broader commercial opportunities in medical laser therapy

Lund, Sweden, [date] – Clinical Laserthermia Systems AB (publ) ("CLS") today announces that it has entered into a strategic partnership agreement with advanced fiber tools GmbH ("AFT") to jointly pursue new commercial opportunities by combining CLS's proprietary non-cooled laser technology with AFT's expertise in fiber-optic engineering and manufacturing.

Building on their established manufacturing collaboration, the companies aim to identify and develop specialized medical laser products for therapeutic uses across a broad range of markets beyond CLS's existing partnerships in neurosurgery and urology. CLS believes the combined commercial potential of these additional markets could exceed that of its currently targeted markets, creating opportunities for long-term growth and diversification.

"This agreement is an important step in unlocking the broader commercial potential of our technology. While our current business is focused primarily on neurosurgery, we believe there are significant opportunities across additional therapeutic areas that remain largely untapped by CLS. Together with AFT, we aim to pursue these opportunities through a resource-efficient, partnership-led approach," says Dan Johansson Mogren, CEO of CLS.

"Our long-standing collaboration with CLS provides a strong foundation for further innovation. By combining our complementary technologies and expertise, we see opportunities to develop differentiated products addressing new therapeutic needs," says Naim Ashraf, CSO of advanced fiber tools GmbH.

The agreement establishes a non-exclusive framework for evaluating and pursuing opportunities, with individual development and commercialization projects to be agreed separately. It does not involve immediate financial commitments or guaranteed commercial volumes and does not affect the companies' existing Manufacturing Agreement.

About advanced fiber tools GmbH
advanced fiber tools GmbH is a German company specializing in the development and manufacturing of advanced fiber-optic products and customized solutions for medical and other specialized applications. For more information about AFT, please visit the Company's website: advanced fiber tools GmbH

For more information, please contact:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-post: dan.mogren@clinicallaser.com

About CLS
Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG® Thermal Therapy System and ClearPoint Prism® Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold through partners for image-guided laser ablation. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: www.clinicallaser.se

This disclosure contains information that CLS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 19-11-2026 08:30 CET.